BioNTech's May Agenda Puts Cash and Cancer Trials in the Spotlight

BioNTech's strategic shift to oncology faces a critical test with Q1 earnings and a shareholder vote on new capital and board expansion in May 2025.

Investors in BioNTech are bracing for a pivotal month, with the company’s strategic pivot from pandemic windfalls to a cancer-focused future entering a critical phase. The stock, which closed at €87.00 on Friday, has rallied nearly 20% from its 52-week low of €72.50, yet the coming weeks will test the market's confidence in this expensive transformation.

All eyes are first on the quarterly report due May 5. Analysts anticipate a loss of €2.31 per share, with revenue expected to be around €168 million. This figure underscores a broader forecast: management projects full-year revenue will decline significantly to just over €2 billion. The company’s substantial cash reserve of €17.2 billion provides a crucial buffer against these shrinking Covid-related sales and funds the aggressive clinical push.

That clinical ambition is central to BioNTech's new identity. The pipeline is expanding rapidly, with nine Phase III trials currently underway in oncology. The company plans to initiate six additional late-stage study programs before year-end. Promising data for an antibody-drug conjugate candidate in uterine cancer recently prompted Bank of America to raise its price target to $130, highlighting the pipeline's potential.

However, the transition is not without its stumbles. A major U.S. trial for an updated Covid-19 vaccine, run with partner Pfizer, was halted due to insufficient participant enrollment. This setback increases pressure on the oncology division, which the company admits will not generate meaningful commercial revenue until 2027 at the earliest.

Ten days after the earnings release, shareholder focus shifts to governance and capital. At the virtual Annual General Meeting on May 15, investors will vote on expanding the Supervisory Board from six to eight members, adding two specialists in oncology to steer the strategic shift. A more consequential item on the agenda is a request for new authorized capital amounting to roughly €130 million, equivalent to 50% of the current share capital. This move would grant management significant financial flexibility for future funding needs.

Also up for approval is a domination and profit transfer agreement with subsidiary BioNTech Discovery GmbH, aimed at tax optimization. This structure would allow losses from the parent company—which totaled €1.14 billion last fiscal year—to be offset against profits from the subsidiary.

The immediate market reaction appears robust, with the stock posting a weekly gain of nearly 10% and trading just above its 50-day moving average. A positive outlook on the cancer pipeline in the upcoming quarterly report could see the share price challenge the 200-day line near €88. Yet the path forward remains costly and long, with the company’s ability to manage its cash burn and deliver on late-stage clinical promises defining the investment thesis for the years ahead.